Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling

20 Apr 2020

Abstract excerpt

Immune-checkpoint therapy has failed to show significant benefit in glioblastoma (GBM) patients. Immunologic subtypes of GBM are necessary to identify patients who might benefit from immune-checkpoint therapy. This study reviewed 152 GBM samples from The Cancer Genome Atlas (TCGA) and 214 GBM samples from Chinese Glioma Genome Atlas (CGGA). Correlation analysis showed that immune checkpoint genes (ICGs) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32310827
DOI: 10.18632/aging.103065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profilingPMID 32310827Read ↗

Development of a prognostic model of glioma based on immune‑related genesSemantic proximity Read ↗

Establishment and validation of an immune-based prognostic score model in glioblastoma.Semantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

Identification of an Immune-Related Prognostic Risk Model in GlioblastomaSemantic proximity Read ↗

Identification of an Immune-Related Prognostic Signature for Glioblastoma by Comprehensive Bioinformatics and Experimental AnalysesSemantic proximity Read ↗

Identification of a Potential Prognostic Signature based on Immune-related Genes in Primary GlioblastomaSemantic proximity Read ↗

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade GliomasSemantic proximity Read ↗

Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for GlioblastomaSemantic proximity Read ↗

Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic playersSemantic proximity Read ↗

Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of GlioblastomasSemantic proximity Read ↗

Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastomaSemantic proximity Read ↗

Predictive Analyses of Prognostic-Related Immune Genes and Immune Infiltrates for GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.